12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Other News

Myrexis cancer news

Myrexis said it would restructure and reduce headcount by 15 (19%) to 62 after discontinuing development of Azixa verubulin earlier this year. The small molecule microtubule destabilizing apoptosis-inducer was in Phase IIb testing for glioblastoma multiforme...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >